Our People

Kate Gartlan

Associate Professor | Team Head

Immunopathology

+61 7 3845 3774

kate.gartlan@qimrberghofer.edu.au

 

CURRENT APPOINTMENTS

2019-current: Team Head, Immunopathology Laboratory

2018-current: Senior Fellow, University of Queensland

2019-current: Adjunct Associate Professor, Queensland University of Technology

 

PREVIOUS APPOINTMENTS

2019: Senior Staff Scientist, Fred Hutchinson Cancer Research Center

2015-2018: Fellow, University of Queensland

2016-2018: Senior Research Officer, Bone Marrow Transplantation Laboratory

2012-2016: Research Officer, Bone Marrow Transplantation Laboratory, QIMR Berghofer

2009-2012: Postdoctoral Researcher, Sir William Dunn School of Pathology, University of Oxford

 

ORCID NUMBER

0000-0002-0343-1274

 

RESEARCHER ID

 C-5315-2009

 

CURRENT AREA OF RESEARCH

Associate Professor Kate Gartlan is an immunologist with a strong interest in adaptive immune polarization and extensive experience using in vivo models to investigate inflammation and cellular immunity. Her research has been primarily focused on cytokines and the early factors that influence T cell polarization, which she has investigated in a variety of inflammatory contexts including, vaccine design, infection, allergy, transplantation and autoimmunity.

Associate Professor Gartlan has developed valuable expertise in transplant biology, murine models of GVHD, engraftment as well as translational research experience through her ongoing participation in clinical studies.

The impact of her research has led to important international collaborations in both academia and industry to investigate novel approaches to modulating inflammatory cytokine responses.

RESEARCH HIGHLIGHTS

  • established a novel in vivo model of allograft rejection as part of a large international collaboration to develop small molecule inhibitors of Perforin
  • recently completed three studies investigating on the influence of Th17, Tc17 and Th22 in allotransplantation and received competitive funding to elaborate this work
  • contributed to a successful phase I/II clinical trial and current phase III trial at QIMRB/RBWH using a novel strategy to target inflammatory pathways post-transplant through IL-6 inhibition

PROFESSIONAL MEMBERSHIPS

2017-current: AAI (American Association of Immunologists), Member

2015-current: TSANZ (Transplantation Society of Australia & NZ), Member

2003-current: ASI (Australasian Society of Immunology), Member

2015-2017: QIMR Berghofer Postdoctoral Society, Committee Member

2009-2012: BSI (British Society of Immunology), Member

 

EDUCATIONAL BACKGROUND

2009: Doctor of Philosophy, Burnet Institute/Victoria University

2000: Bachelor of Science (Hons), La Trobe University